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Background: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment
for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not
demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged
19–88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of
patients60 years treated on the R-CHOP14v21 trial with extended follow-up.
Patients and methods: Six hundred and four R-CHOP14v21 patients60 years were included in this subgroup analysis, with a
median follow-up of 77.7months. To assess the impact ofMYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on
outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21
(N¼ 217) and RICOVER-60 (N¼ 204) trials.
Results: Elderly DLBCL patients received high dose intensities with median total doses of98% for all agents. Toxicities were
similar in both arms with the exception of more grade3 neutropenia (P< 0.0001) and fewer grade3 thrombocytopenia
(P¼ 0.05) in R-CHOP-21 versus R-CHOP-14. The elderly patient population had a favorable 5-year overall survival (OS) of 69%
(95% CI: 65–73). We did not identify any subgroup of patients that showed differential response to either regimen. In
multivariable analysis including individual factors of the IPI, gender, bulk, B2M and albumin levels, only age and B2M were of
independent prognostic significance for OS. Molecular analyses demonstrated a significant impact ofMYC-R (HR¼ 1.96; 95% CI:
1.22–3.16; P¼ 0.01) and DHL (HR¼ 2.21; 95% CI: 1.18–4.11; P¼ 0.01) on OS in the combined trial cohorts, independent of other
prognostic factors.
Conclusions: Our data support equivalence of both R-CHOP application forms in elderly DLBCL patients. Elderly MYC-R and
DHL patients have inferior prognosis and should be considered for alternative treatment approaches.
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Introduction
Elderly patients with diffuse large B-cell lymphoma (DLBCL)
have a worse prognosis compared to the younger patient popula-
tion. This is partly explained by lower treatment tolerability in
elderly patients with difficulties to administer adequate doses of
chemotherapy. However, even when receiving comparable treat-
ment intensities, elderly DLBCL patients have inferior outcome,
potentially indicating more aggressive disease biology. Therefore,
dose-intensified administration of R-CHOP immunochemother-
apy might be of particular benefit for elderly DLBCL patients to
overcome these high-risk factors. Treatment of patients
>60 years (y) with 6 R-CHOP-14 plus 2 rituximab in the
German RICOVER-60 trial has achieved the best long-term out-
come in elderly DLBCL patients published to date [1]. However,
superiority of dose-intensified R-CHOP-14 compared to the 3-
weekly administration in elderly DLBCL patients could not be
demonstrated in randomized trials.
The GELA LNH03-6B trial comparing R-CHOP-14 and R-
CHOP-21 in DLBCL patients aged 60–80y showed no difference
of either regimen [2], but results were criticized due to high
treatment-related mortality and low dose intensities in the R-
CHOP-14 arm. The UK NCRI R-CHOP14v21 trial compared the
2- and 3-weekly R-CHOP regimens in DLBCL patients aged 18–
88y and similarly did not observe a difference in outcome across
age groups [3]. However, outcomes of the elderly R-CHOP14v21
trial cohort have not been reported separately and it remained
unclear whether particular subgroups of elderly patients benefit
from intensified treatment.
The International Prognostic Index (IPI) is widely used for
prognostication of younger and elderly DLBCL patients. Due
to differences in disease biology and outcomes it has been pro-
posed to use separate prognostic scores for the elderly patient
group [4, 5], but these have not yet been validated in large inde-
pendent cohorts.
Several molecular high-risk markers have been identified in
DLBCL that could potentially refine clinical prognostic models.
Cell-of-origin (COO) assessment of DLBCL according to gene-
expression-profiling separates the germinal center B-cell (GCB)
and the poor prognostic activated B-cell (ABC) subtypes, but
these analyses lack prospective validation and methodological
problems currently limit their use in standard practice. The nega-
tive prognostic impact of MYC rearrangements (MYC-R) as well
asMYC- and concomitant BCL2- or BCL6 rearrangements (dou-
ble-hit lymphoma; DHL) has been shown in several DLBCL co-
horts [6, 7]. The prognostic significance of MYC-R seems to be
particularly high in older DLBCL patients [6]. Due to the low in-
cidence of MYC-R and DHL and possibly due to their age-
dependent relevance, an independent prognostic significance of
these markers in multivariate models has not yet been demon-
strated in prospective trial cohorts of R-CHOP-treated patients.
The aim of this subgroup analysis was to provide detailed out-
comes and toxicity data on elderly patients treated within the
R-CHOP14v21 trial and to investigate the impact of clinical and
molecular factors on outcome in this age group.
Patients and methods
Patient characteristics in the R-CHOP14v21 trial have been published in
detail [3]. A brief description of the trial is given in the Supplement
(available at Annals of Oncology online).
Of 1080 R-CHOP14v21 patients, 604 were60y and included in the
current analysis. Details of statistical analyses are provided in the
Supplement.
COO was assessed by the immunohistochemistry (IHC)-based Hans
algorithm. Assessment of MYC-, BCL2- and BCL6-rearrangements was
done with fluorescence in situ hybridization (FISH; N¼ 217). DHL was
defined as presence ofMYC- and either BCL2- or BCL6-rearrangements.
In order to increase the sample size to assess the impact of MYC-R and
DHL on outcome in elderly DLBCL patients, we performed a joint ana-
lysis with data from 204 elderly DLBCL patients treated on the
RICOVER-60 trial who had molecular results available (supplementary
Table S1, available at Annals of Oncology online). Details of the German
high-grade non-Hodgkin lymphoma study group (DSHNHL)
RICOVER-60 trial and methods of molecular analyses within the trial
have been previously described [1, 7].
Results
We included 604 elderly patients from the R-CHOP14v21 trial in
this subgroup analysis. Patients’ median age was 67y (range 60–
88). Baseline characteristics were well balanced between treat-
ment arms (Table 1). There was a trend towards a higher rate of
BCL6 rearrangements and DHL in R-CHOP-14 (P¼ 0.10 and
P¼ 0.06, respectively).
Dose intensities were high in both trial arms. Median total
doses of cyclosphosphamide, doxorubicin, vincristine, prednisol-
one and rituximab received were 98% versus 99%, 98% versus
99%, 100% versus 100%, 98% versus 100%, and 98% versus 98%
in R-CHOP-21 and R-CHOP-14, respectively. Seventy-one
(24%) patients on R-CHOP-21 and 46 (15%) patients on R-
CHOP-14 did not complete all treatment cycles (P¼ 0.01).
Reasons for early treatment termination are listed in supplemen-
tary Table S2, available at Annals of Oncology online, with
treatment-related toxicity being the most common cause.
Frequency of dose reductions was similar in both arms (15% for
R-CHOP-21 versus 16% for R-CHOP-14; P¼ 0.73).
Treatment toxicities are given in Table 2. There was evidence of
more grade3 neutropenia (62% versus 36%; P< 0.0001) and
less grade3 thrombocytopenia (7% versus 12%; P¼ 0.05) in R-
CHOP-21 compared to R-CHOP-14. Patients on R-CHOP-21
had lower incidence of anemia (20% versus 31%; P¼ 0.001),
with a similar trend for grade3 anemia (2% versus 5%;
P¼ 0.11). No significant difference in the incidence of fever and
infections or any other toxicity was observed. The incidence of
treatment-related deaths, fatal cardiac events and secondary
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malignancies were similar in both arms (supplementary Table S3,
available at Annals of Oncology online).
Response was assessable in 274 patients in each arm. There was
no evidence of a difference in response rates between R-CHOP-
21 and R-CHOP-14 [complete response (CR)/unconfirmed CR
(CRu): 67% versus 62%, P¼ 0.21; overall response rate (ORR)
both 91%; Table 3]. CR/CRu rates after four cycles of therapy
were 39% and 33%, respectively (P¼ 0.15). 61% and 60% of pa-
tients are still alive without progression (supplementary Table S3,
available at Annals of Oncology online). Four patients on R-
CHOP-21 and seven on R-CHOP-14 presented with central ner-
vous system relapse (P¼ 0.55).
After a median follow-up of 77.7months, there was no evi-
dence of a difference in progression-free survival (PFS) and over-
all survival (OS) between treatment arms in patients60y
or70y (Figure 1A-D). No difference in survival between R-
CHOP-21 and R-CHOP-14 was observed in patients who only
achieved partial response (PR) after four cycles (P¼ 0.79 for PFS;
P¼ 0.68 for OS). There was also no difference between treatment
arms with respect to gender (P¼ 0.54 for PFS; P¼ 0.67 for OS)
or IPI (P¼ 0.64 for PFS; P¼ 0.50 for OS). 5y-PFS was 64% (95%
CI: 60-68) in patients60y and 58% (95% CI: 51-65) in pa-
tients70y. 5y-OS was 69% (95% CI: 66–73) and 61% (95% CI:
54–68), respectively.
63/280 (23%) patients with available data received consolida-
tion radiotherapy. Of those, 36 had initial bulk, 20 extranodal dis-
ease, and 10 had both. Disease status before radiotherapy was
available for 61 patients: 23 (37%) CR/CRu, 31 (51%) PR and 7
(12%) SD. In patients with PR or SD who are supposed to benefit
most from radiotherapy, the use of radiotherapy was not associ-
ated with OS (supplementary Figure S3, available at Annals of
Oncology online).
Inmultivariable analysis, only age and B2M levels were of inde-
pendent prognostic significance for OS (supplementary Table S4,
Table 1. Baseline characteristics
Characteristics R-CHOP-21 R-CHOP-14
(N5301) (N5303)
n (%) n (%)
Age (years)
60–69 192 (64) 196 (65)
70 109 (36) 107 (35)
Sex
Female 148 (49) 150 (50)
Male 153 (51) 153 (50)
WHO performance status
0 120 (40) 143 (47)
1 132 (44) 118 (39)
2 49 (16) 42 (14)
Stage (N¼596)
IA 9 (3) 9 (3)
IB 6 (2) 7 (2)
II 90 (30) 83 (28)
III 91 (31) 104 (35)
IV 102 (34) 95 (32)
Bulk (N¼601) 139 (47) 126 (42)
B symptoms 121 (40) 134 (44)
Elevated LDH 200 (66) 197 (65)
>1 extranodal sites 94 (31) 82 (27)
IPI score
1 48 (16) 44 (15)
2 75 (25) 90 (30)
3 98 (33) 104 (34)
4 66 (22) 56 (18)
5 14 (5) 9 (3)
Subtype (N¼317)
GCB 76 (50) 82 (50)
Non-GCB 77 (50) 82 (50)
b2-microglobulin 3mg/L (N¼371) 88 (51) 102 (52)
Albumin 35g/L (N¼598) 100 (34) 86 (29)
MYC rearrangement (N¼217) 9 (9) 14 (12)
BCL2 translocation (N¼220) 26 (25) 33 (28)
BCL6 rearrangement (N¼218) 17 (16) 30 (26)
Double-hit abnormality (N¼215) 5 (5) 9 (8)
Table 2. Most common grade3 toxicities and cause of treatment-related
deaths
R-CHOP-21 (N5301) R-CHOP-14 (N5303)
Any grade Grade 3 Any grade Grade 3
All toxicities 292 (97%) 216 (72%) 299 (99%) 182 (60%)
Neutropenia 224 (74%) 185 (61%) 138 (46%) 109 (36%)
Thrombocytopenia 73 (24%) 22 (7%) 112 (37%) 37 (12%)
Anemia 60 (20%) 6 (2%) 95 (31%) 14 (5%)
Infection 145 (48%) 71 (24%) 146 (48%) 71 (23%)
Fever 70 (23%) 16 (5%) 56 (18%) 16 (5%)
Mucositis 143 (48%) 4 (1%) 167 (55%) 8 (3%)
Nausea 188 (62%) 7 (2%) 151 (50%) 12 (4%)
Vomiting 98 (33%) 7 (2%) 82 (27%) 9 (3%)
Diarrhoea 109 (36%) 12 (4%) 113 (37%) 16 (5%)
Constipation 185 (61%) 7 (2%) 160 (53%) 8 (3%)
Neurological 167 (55%) 23 (8%) 183 (60%) 36 (12%)
Fatigue 240 (80%) 31 (10%) 252 (83%) 40 (13%)
Bone pain 68 (23%) 7 (2%) 102 (34%) 6 (2%)
Cardiac 29 (10%) 2 (1%) 29 (10%) 9 (3%)
Treatment-related deaths: 3 in R-CHOP-21: 2 nonneutropenic sepsis
and 1 neutropenic sepsis; and 7 in R-CHOP-14: 2 nonneutropenic sep-
sis, 1 neutropenic sepsis, 1 renal failure and 3 not speciﬁed.
Table 3. Response to treatment
End of treatment response R-CHOP-21 R-CHOP-14
(N5274) (N5274)
n (%) n (%)
Complete response (CR) 145 (53) 119 (43)
Unconﬁrmed complete response (CRu) 39 (14) 50 (18)
Partial response 64 (23) 80 (29)
Stable disease 16 (6) 16 (6)
Progressive disease or relapse 10 (4) 9 (3)
CR/Cru 184 (67) 169 (62)
Overall response rate 248 (91) 249 (91)
Original article Annals of Oncology
1542 | Ku¨hnl et al. Volume 28 | Issue 7 | 2017
available at Annals of Oncology online). There was no significant
impact of COO subtypes on outcomes (supplementary Figure S1,
available at Annals of Oncology online). When comparing prog-
nostic scores IPI, R-IPI, E-IPI and ABE4 (supplementary Table
S5 and Figure S2, available at Annals of Oncology online), ABE4
achieved the best fit and discrimination for predicting OS, fol-
lowed by the IPI. Similar results were obtained for PFS (data not
shown).
To assess the impact ofMYC-R and DHL on outcome we per-
formed a joint analysis with cases from RICOVER-60. 23/217
(11%) patients from our cohort and 19/204 (9%) patients from
RICOVER-60 had MYC-R as determined by FISH. 14/215 (7%)
and 9/182 (5%) had DHL, respectively. MYC-R and DHL cases
had significantly worse OS compared to cases without these
abnormalities [HR¼ 1.96 (95% CI: 1.22–3.16); P¼ 0.01 and
HR¼ 2.21 (95%CI: 1.18–4.11); P¼ 0.01, respectively); Figure 2].
Similar effect sizes were observed after adjusting for individual
IPI factors and trial arms [HR¼ 1.76 (95% CI: 1.09–2.85);
P¼ 0.02 and HR¼ 2.08 (95% CI: 1.11–3.90); P¼ 0.02,
respectively)]. The difference in OS between DHL and MYC-R
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Figure 1. Kaplan–Meier curves of PFS and OS in (A-B) patients over 60 years and (C-D) patients over 70 years.
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was not significant (HR¼ 1.38 (95% CI: 0.55–3.43; P¼ 0.49).
There was no significant impact of BCL2- or BCL6-rearrange-
ments on OS (P¼ 0.34 and P¼ 0.99, respectively).
Discussion
With a median follow-up of 6.5y, we provide a detailed analysis
of outcome and toxicities from patients with newly diagnosed
DLBCL aged60y treated on the phase 3 R-CHOP14v21 trial.
Elderly DLBCL patients in our cohort had an excellent long-
term outcome with 5y-OS of 69% (3y-PFS 71%; 3y-OS 76%).
These results are similar to data from elderly DLBCL patients
treated with 6 R-CHOP-14 on RICOVER-60 (3y-PFS 73%; 3y-
OS 78%) and better than outcomes in the GELA LNH03-6B trial
(3y-PFS 61%; 3y-OS 73%) [1, 2]. Of note, patients’ median age
was higher in LNH03-6B (70y) compared to our cohort (67y)
and RICOVER-60 (68y). In addition, there were more cases pre-
senting with high IPI (3–5) in the LNH03-6B trial (75% versus
57% in our subgroup versus 43% in RICOVER-60), which might
have contributed to inferior outcome seen in this trial
population.
Toxicity profiles in our cohort of elderly DLBCL patients were
favorable in both treatment arms. As expected, patients on R-
CHOP-21 had a higher incidence of neutropenia probably due to
reduced use of G-CSF, but less thrombocytopenia. Importantly,
there was no difference in infectious complications or treatment-
related deaths. The incidence of deaths during chemotherapy was
very low at 1.7%, suggesting adequate management of elderly pa-
tients in participating centers. In the LNH03-6B trial, a high
treatment-related mortality of 9% was observed in the initial re-
cruitment period, which improved towards the end of the study,
indicating gain of clinical experience with dose-intensified treat-
ment in elderly patients. With 6.5y median follow-up, there was
no difference in long-term toxicity, specifically cardiac events
and secondary malignancies, between arms.
Dose intensities were high in both arms and as seen in the en-
tire R-CHOP14v21 trial cohort [3]. The low dose intensity of
88% for R-CHOP-14 in the LNH03-6B trial could have poten-
tially underestimated efficacy of the 2-weekly regimen. Our re-
sults support equivalence of both regimens in elderly DLBCL
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Figure 2. Kaplan–Meier curves of OS according to MYC- and BCL2 rearrangements and double-hit abnormality in R-CHOP treated elderly pa-
tients from R-CHOP14v21 (N¼ 215) and RICOVER-60 (N¼ 182).
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patients when adequate doses are achieved. However, the study
was not powered for this post hoc subgroup analysis in elderly
patients.
We did not identify any subgroup of elderly DLBCL patients
that showed differential response to either regimen, including
gender and IPI groups. No difference between treatment arms
could be seen in patients70y. An analysis of patients80y was
not feasible due to low numbers (N¼ 20). Moreover, there was
no benefit of dose-intense treatment in late responders who had
not achieved CR/Cru after four cycles.
Consolidation radiotherapy was at the discretion of the investi-
gators and performed in 23% of elderly patients with available
data. The main indication for radiotherapy was initial bulky or
extranodal disease. The benefit of radiotherapy to initial bulk in
elderly DLBCL patients is reported to be greatest for patients who
are not in CR/CRu after induction therapy [8]. Accordingly,
most patients in our analysis received radiotherapy to PR or SD
at the end of treatment, without evidence of a survival benefit for
this strategy. However, these data have significant limitations
(nonrandomized approach, small numbers). In addition, no
PET-CT data were recorded. The on-going DSHNHL
OPTIMAL> 60 trial will investigate whether consolidation
radiotherapy can be safely omitted in elderly DLBCL patients
who are PET-negative at the end of treatment.
Remarkably, PFS of elderly patients was only 8 percentage
points worse at 5y compared to younger patients (5y-PFS 64%
versus 72%), supporting the concept of treating elderly patients
with full doses of chemotherapy whenever possible. Toxicities
were also similar between elderly and younger patients (data not
shown), besides a significantly higher rate of grade3 neutro-
penia in elderly (P0.001).
Differences between DLBCL of elderly and younger patients
have been described on the molecular level, with higher frequen-
cies of ABC subtypes, BCL6 rearrangements, gains in 1q21, 18q21,
and 7q21, and a higher genetic complexity associated with increas-
ing age [9]. We did not observe material differences in the fre-
quency ofMYC-R, BCL6- and BCL2-rearrangements between age
groups, nor in the incidence of IHC-based cell-of-origin subtypes
(data not shown). We found lower frequency of bulky disease and
higher B2M levels in elderly compared to younger patients, imply-
ing differences in disease biology between both groups.
Age-specific clinical and molecular features suggest the need
for a separate prognostic scoring system for elderly patients. We
compared performances of two recently proposed prognostic
scores for elderly DLBCL (ABE4 [5] and E-IPI [4]) with the
standard IPI and R-IPI in our cohort. Both scores use an age cut-
off of 70y. ABE4 further incorporates bulky disease and separates
PS 1 instead of 2. The ABE4 performed best in our cohort,
despite bulky disease not being significantly associated with pa-
tient outcomes. Therefore, separating patients with PS 0 from
those with PS 1 could be a more appropriate cut-off in an eld-
erly patient group. Both ABE4 and IPI distinguished meaningful
prognostic groups for PFS and OS. However, clinical utility of the
ABE4 score might be limited by the fact that only 9% of patients
from our cohort were in the high-risk group compared with 14%
in the original Czech Lymphoma Registry [5]. As discussed by
Ziepert et al. [10], introduction of new scores have to be seen
with caution and should only be considered if properly validated
and if changing patients’ management. The main use of the IPI
has been in the context of clinical trials, allowing risk-
stratification of patients and facilitating comparison of results
across trials. A NCCN-IPI has recently been proposed which sep-
arates three different age groups as risk factors [11]. The great dis-
advantage of this score is that it cannot be used for elderly and
young patient groups separately and is therefore unsuitable for
age-specific DLBCL trials. In contrast, the IPI as age-adjusted IPI
has been validated in both young and elderly DLBCL.
In line with previous findings, IHC-based cell-of-origin classi-
fication did not impact on outcomes, further underscoring limi-
tations of this method. However, final analyses of the REMoDL-B
trial will reveal if the concept of cell-of-origin classification as
prognostic marker holds true when assessed prospectively [12].
Our combined analysis of FISH data from R-CHOP14v21 and
RICOVER-60 demonstrates for the first time independent prog-
nostic significance of both MYC-R and DHL in patients treated
with R-CHOP within prospective cohorts. A negative prognostic
impact of MYC-R and DHL has been reported in several hetero-
geneous DLBCL populations, but did not reach independent sig-
nificance in trial cohorts due to small numbers [3, 7]. On-going
prospective trials will reveal if these patients benefit from upfront
treatment intensification.
In conclusion, our data demonstrate excellent short and long-
term results with both R-CHOP-14 and R-CHOP-21 in elderly
DLBCL patients. This analysis contributes important information
to the longstanding discussion about optimal management of the
elderly DLBCL patient population and provides a detailed analysis
ofmolecular and clinical prognostic factors in this age group.
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